Elicio Therapeutics Inc (ELTX)
8.43
-0.42
(-4.75%)
USD |
NASDAQ |
May 24, 16:00
8.43
0.00 (0.00%)
After-Hours: 19:54
Elicio Therapeutics Cash from Financing (Quarterly): 11.02M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 11.02M |
| December 31, 2023 | 7.002M |
| September 30, 2023 | 0.059M |
| June 30, 2023 | 21.51M |
| Date | Value |
|---|---|
| March 31, 2023 | 10.04M |
| March 31, 2021 | 5.116M |
| March 31, 2020 | 7.512M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
0.059M
Minimum
Sep 2023
21.51M
Maximum
Jun 2023
8.895M
Average
7.512M
Median
Mar 2020
Cash from Financing (Quarterly) Benchmarks
| Immuneering Corp | 0.9799M |
| Outlook Therapeutics Inc | 56.14M |
| Amylyx Pharmaceuticals Inc | 0.131M |
| NovaBay Pharmaceuticals Inc | -0.597M |
| Palatin Technologies Inc | 9.136M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -12.12M |
| Cash from Investing (Quarterly) | 0.003M |
| Free Cash Flow | -36.68M |
| Free Cash Flow Per Share (Quarterly) | -1.180 |
| Free Cash Flow Yield | -55.50% |